PLAVIX® APPROVED IN JAPAN
PLAVIX® APPROVED IN JAPAN Paris - January 24, 2006 - Sanofi-aventis (EURONEXT : SAN and in New York NYSE : SNY) announced today that the antiplatelet agent Plavix® (clopidogrel) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the reduction of recurrence after ischemic cerebrovascular disorder. Since September 2005, all commercial rights for Plavix® in Japan belong to sanofi-aventis. Sanofi-aventis and Daiichi Pharmaceuticals Co., Ltd. have agreed to collaborate in the future in the areas of manufacturing and co-promotion to ensure the success of